FT : Spain probes cyber weaknesses at small power plants after blackout

Spain probes cyber weaknesses at small power plants after blackout
Madrid says ‘everything remains on the table’ as it seeks to identify the cause of massive April 28 outage

Spain is demanding information from small electricity generators on their cyber defences as investigators probing last month’s blackout seek to determine whether they were a weak link exploited by bad actors to bring down the country’s power grid.

The questions from Spain’s National Cybersecurity Institute (Incibe) will intensify the debate about whether the country’s dependence on renewable energy was to blame for the power outage, a contention dismissed by Prime Minister Pedro Sánchez, a champion of decarbonisation.

Senior government officials have “concerns” about the robustness of cyber defences at small and medium-sized power facilities, notably the solar and wind farms that have proliferated as Spain became a global renewables leader, said one person familiar with the matter.

Spain has yet to identify the root cause of the collapse of the Iberian power grid on April 28 and has not discounted a cyber attack. “As of today, we are not ruling out any possibilities. Everything remains on the table,” said Spain’s energy and environment ministry.

Separately, a judge at Spain’s National High Court has opened an investigation into whether a cyber attack was behind it.

Spanish grid operator Red Eléctrica said on the day after the outage that there was no evidence of a cyber attack on its own facilities, but has not commented since then.

The government said last week that Spain suffered 100,000 cyber attacks across all sectors last year, with 70 per cent of them targeting companies or other organisations, as it announced a €1.1bn investment to reinforce cyber security.

Three companies that own or operate renewable power plants told the Financial Times they had received a barrage of questions about the blackout and their own defences from or Incibe, as part of official inquiries into what happened.

The questions included “Is it possible to control the power plant remotely?”, “Were any anomalies detected prior to the 28 April incident?” and “Have you installed any recent security patches or updates?”

One government official said the authorities were pursuing multiple lines of inquiry and that Incibe’s questions were not a sign that one hypothesis about the blackout was being given more weight than others.

Spain’s renewable energy boom has ended the country’s traditional model in which electricity generation was concentrated in a few big, highly-regulated fossil fuel or nuclear power plants.

Instead Spain has shifted to a system of thousands of smaller generators, which has created more targets for hackers wanting to wreak havoc by injecting malware or disrupting power flows.

Potential entry points into the system, all linked to the internet, include firmware-run devices that convert electricity into a safe current, and communication channels between generating units and control centres.

Red Eléctrica says it receives live data from 4,000 renewable installations that have a generation capacity of at least 1 megawatt. It can send instructions in real time to modify the production of those that are 5MW or larger.

But in its latest annual report Red Eléctrica’s parent company identified as a risk having “insufficient information for the real-time operation of the system due to an increase in renewable generation facilities with outputs below 1MW”.

Anpier, a trade group, estimates that Spain has about 54,000 solar installations connected to the grid, including small-scale rooftop arrays at factories, offices and homes.

Several Spanish electricity executives said they doubted that a cyber attack caused the blackout — in part because of the difficulty of executing one with such a dramatic impact. But they conceded that an assault in a form not previously conceived could not be ruled out.

Miguel López, regional sales director in southern Europe for cyber security group Barracuda, said: “With the information that we have available at the moment, a cyber attack doesn’t seem to be the most plausible hypothesis, because there would have needed to be several very well co-ordinated attacks on several different agents.”

If hackers had succeeded in “breaking” something it would have taken much longer than the 16 hours Spain needed to fully restore grid functioning, López added.

Anpier said: “In general . . . small photovoltaic installations do not have systems that can be attacked and that can cause electrical problems remotely. Moreover, it is impossible for a one-off disturbance in installations of this size to have an influence on the system.”

The blackout occurred after Spain lost 15 gigawatts of electricity — 60 per cent of its supply — in just five seconds, destabilising the grid and causing multiple other power stations to disconnect. Before the outage renewables were contributing 70 per cent of Spain’s electricity.

FT : Uncertainty hangs over Europe’s EV sales resurgence

Uncertainty hangs over Europe’s EV sales resurgence
Demand for battery-run cars strong in first quarter but analysts warn trend may not continue

Sales of electric vehicles have enjoyed a resurgence in Europe this year but analysts warn that geopolitical turbulence and regulatory uncertainty could threaten their continuing momentum.

A sharp rebound in EV demand across the continent has been one of the few bright spots for carmakers at a time when Porsche, Volvo Cars, Mercedes-Benz and others have reduced or withdrawn their earnings forecasts due to the turmoil caused by Donald Trump’s rapidly evolving tariff war.

Registrations of new electric cars in wider Europe and the UK have increased 28 per cent to 573,500 vehicles during the first three months of the year, driven by a sharp recovery in Germany, according to European car industry body ACEA.


At Volkswagen quarterly sales of EVs in the continent have more than doubled, with every one in five cars sold in western Europe now fully electric. BMW also reported a 64 per cent year-on-year jump in EV retail sales in Europe from January to March, while global sales of EVs at Renault increased 88 per cent. 

Tesla was one of the few exceptions, with its EV sales in Europe declining 37 per cent during the same period as the consumer backlash against Elon Musk’s political activism continued. 

Analysts say the broader rebound in EV sales across Europe had been expected since many carmakers had delayed sales of their new EV models until early this year to make it easier for them to meet the EU’s tougher emissions regulations. Cheaper offerings of electric cars below €25,000, such as the Renault 5 and Citroën ë-C3, also boosted consumer demand. 

At an earnings briefing in late April, Fabrice Cambolive, chief executive of the Renault brand, said the success of the Renault 5 showed that the small car segment was capable of shifting to fully electric vehicles. “This is a big trend,” he added. 

Renault’s strong sales came even as EV sales in France have fallen 7 per cent in the first quarter following the removal of generous government subsidies that bolstered EV sales in early 2024. The government will introduce more subsidies in the second half of the year but the package is set to be less generous, said Marie-Laure Nivot, head of automotive analysis at AAA.

In Germany, the return of corporate customers facing the expiry of subsidised lease contracts from 2022 was prompting a fresh wave of vehicle orders, said automotive analyst Matthias Schmidt.

Daniel Schwarz, analyst at Stifel, added that the long-term trend of falling electric vehicle prices, coupled with rising costs for combustion engine cars, have supported a steady uptick in EV demand. 

Despite the latest encouraging data, a continued rise in EV demand will not be a straight line.

The EU’s recent decision to ease its emissions regulations for combustion engine vehicles, though welcomed by carmakers, “could temporarily slow battery electric vehicle penetration (BEV) in the EU” as it reduces pressure for an aggressive rollout for car companies, according to Schwarz.

In an interview, Michael Lohscheller, chief executive of EV maker Polestar, said regulators needed to provide clarity for consumers so they do not hesitate to make the electric shift. “Wherever there is uncertainty, people wonder about this,” he added. 

The greater flexibility in the EU’s emissions rules also comes as the industry is under heavy pressure from the policy uncertainty and higher tariffs unleashed by Trump’s trade tensions which could slow costly investments in EVs.

“This is the year where Europe needs to double down on pushing electric cars to the market,” said Chris Heron, secretary-general of trade association E-Mobility Europe. “But things happening globally are going to make that more challenging for everyone.” 

The rise in EV sales is also a double-edged sword for some carmakers because profit margins on electric cars are still lower than petrol vehicles due to high battery costs. For those such as Volkswagen, who do not have an affordable EV on the market, need to offer heavy discounts to persuade consumers to make the electric switch. 

“The significant expansion of BEV volumes, particularly in Europe, as well as the ramp-up costs of numerous new models . . . are expected to burden earnings in 2025,” Arno Antlitz, VW’s chief financial officer, recently told analysts. 

The German group will launch its ID2 — its first EV with a price tag under €25,000 — next year and an even lower priced ID1 in 2027. “With the ID2 family, the margin dilution effect of the BEVs should really then be much smaller than today,” Antlitz added.

FT : US groups raced to stockpile pharmaceuticals ahead of tariffs

US groups raced to stockpile pharmaceuticals ahead of tariffs
Imports of products used by pharma and medical groups surged to a record in March

The US imported a record $53bn of products used in the pharmaceuticals and medical industry in March as companies rushed to build stockpiles in case Donald Trump hits the sector with tariffs.

Imports of pharma products soared around 160 per cent in March from the same month the previous year, and almost doubled from February, reaching the highest on Census Bureau records stretching back to 2002.

The rush to purchase finished products and ingredients that are used to make them is one of the earliest signs of how Trump’s sweeping tariffs on US trading partners are reshaping global business.

Trump has not yet announced levies targeting the pharmaceuticals sector, but companies are preparing for the possibility they might be imposed after the US last month launched a national security review on the subject.

The US president on Monday promised to make European countries pay more for drugs, while calling on pharmaceutical companies to lower prices for US consumers. A White House official noted, however, that tariffs on pharma products were a “separate” matter.


The US and UK said last week they would promptly negotiate “significantly preferential” tariff treatments on drugs and ingredients. The pledge would be contingent on the outcome of Washington’s pharmaceuticals sector probe and UK compliance with supply chain security requirements.

Ireland accounted for $28bn of the imports in March, up from $5.5bn in the same period the previous year. Several US pharmaceutical companies have manufacturing sites in Ireland — lured in part by Dublin’s relatively low corporate tax rate. The country, which is the third-largest exporter of pharmaceuticals globally, has approximately 50 US Food and Drug Administration-approved pharma and biopharma plants.

JPMorgan Chase’s Abiel Reinhart said branded drug developers “will be able to use the import stockpile they are building now to cushion the impact of tariffs while they build out US manufacturing”.

Cuts to US corporate tax rates during the previous Trump administration reduced some of the incentive to manufacture in Europe, he said, but added that “the volume of production in Europe is still high owing to past investments”.

A number of US pharmaceutical groups have recently made announcements about expanding domestic manufacturing. These include Eli Lilly, which in February set out plans for $27bn of investment, while Johnson & Johnson said in March that it would invest more than $55bn in four factories.

On a quarterly earnings call this month, Lilly’s chief executive told investors that “upon completion” of the company’s manufacturing plan, it “will be able to supply medicines for the US market entirely from US facilities, as well as increase the volume of medicines we export”. 

Other US pharmaceutical companies have stressed that they already have a strong domestic manufacturing presence, and that they have set up processes to respond to volatile trade policy.

Biogen, a large biotech group, said in its first-quarter results that it “operates a significant manufacturing presence in the US”, while Pfizer’s chief financial officer told analysts that the company had set up a “cross-functional team” to analyse potential outcomes in the current “fluid environment”. 

Merck chief executive Rob Davis told analysts that while the company’s “biggest exposure” for tariffs was its blockbuster cancer drug Keytruda, it had inventory in the US to last all of 2025. 

Industry figures have warned on the impact of pharmaceutical tariffs, including the chief executive of Johnson and Johnson who said that they could lead to drug shortages. 

The US currently has no tariffs on many pharmaceuticals because of a 1994 World Trade Organization trade deal.

European pharmaceuticals companies are also boosting their US investments in response to the tariff threats. AstraZeneca said this month it was planning further investment in addition to its 11 US production sites, including shifting manufacture of Europe-made products to the country.

UK-listed GSK is planning tens of billions of dollars of investment in manufacturing and research and development in the US over the next five years. 

FT : Can Europe finally fix its capital markets?

Can Europe finally fix its capital markets?
Stung by its lack of competitiveness, the EU is making a new push to create a deep financial market. Some investors believe this time could be different

Markus Villig knows all about Europe’s aversion to investment risk. The chief executive of Estonian ride-hailing app Bolt “met almost every venture capitalist” on the continent before securing most of Bolt’s $1bn-plus in funding from US investors.

“The reason we lost out wasn’t [because rival apps] had a better product. It’s because they had access to more money,” Villig tells the Financial Times. “[US investors] were willing to take the risk, even on an Estonian legal entity. European VCs just couldn’t commit at that level.”

This has become a familiar tale in Europe, as its best companies often look to the deep capital markets in the US instead of seeking backing at home, while other potentially successful companies struggle for finance. Rich in savings, Europe struggles to fund its future.

“[Europe] probably missed out on three to five trillion euros of wealth creation because of this,” Villig argues. “If we don’t fix our capital markets, we’re going to keep losing in tech, in innovation, in everything that matters.”

Stung by the lack of competitiveness of its economy, the issue of its underfunded companies has become one of the top items on the European political agenda.

Brussels is making a new push to foster deeper and more integrated capital markets across the EU, with a focus on reducing fragmentation, improving access to financing and boosting retail investment. Ursula von der Leyen, the European Commission president, has made the project one of the priorities of her second term.

This year, the commission launched the “savings and investments union” initiative, a policy programme aimed at mobilising the EU’s vast pool of household savings and channelling them more effectively into productive investments.

The commission’s proposals include reviving securitisation, centralising supervision and facilitating retail investment — alongside concluding years-long negotiations over insolvency laws and completing the banking union.


For many in Europe’s business and political elite, the issue is not just about venture capital but also what the leakage of European listings to the US represents. Taken together, these problems represent a structural threat, rather than just a missed opportunity.

“Europe has uniquely high savings, but we fail to turn them into productive investment,” says Stéphane Boujnah, the chief executive of Euronext, which operates stock exchanges in seven European countries. “We need to rewire the system — and fast.” ​

The continent’s fragmented financial landscape is a big part of the problem, he adds. Europe’s capital market is in reality a hotchpotch of national systems, each with different rules, regulators and investment cultures. Its most significant financial centre, London, is no longer in the EU.

The contrast with the US, where unified capital markets and post-trade systems alongside a single market regulator underpin a culture of risk-taking and equity investment, is stark.

“You cannot build a thriving equity market on 27 different legal systems and 27 different ideas of supervision,” adds Boujnah.

The idea of trying to forge a more coherent European capital market is not new, however. Indeed, a decade after its launch, what was initially called the EU’s capital markets union (CMU) project remains a work in progress.

Strides have been made in areas such as prospectus reform and improving access to public markets for smaller companies, but Europe’s capital markets are still fragmented and under-developed while its companies remain overly reliant on bank funding. EU firms raise just a third as much financing from capital markets as their US counterparts, and investment flows across member states remain uneven.

“For 20 years European politicians have been discussing the need for better integrated capital markets, and frankly little has been achieved so far,” Polish finance minister Andrzej Domański lamented last month.

Sceptics say that even with reform in specific areas, it will be difficult to encourage a US-style equity culture in a continent where generous welfare and pension systems have removed much of the incentive for citizens to invest in riskier asset classes.

However, EU officials say there is greater political momentum behind the new effort because leaders have acknowledged just how damaging weaker capital markets are to Europe’s economy.

European Central Bank president Christine Lagarde estimates that there are €300bn annual capital flows from the EU to the US. Mario Draghi, a former ECB president and Italian premier, in a widely acclaimed report last year estimated annual EU investment needs in the order of €800bn, only a part of which would be covered by the public purse.

On some issues that are politically sensitive, officials say, there is a willingness to form smaller groups of countries that can push changes — rather than aiming for unanimity.

Some investors believe that momentum may finally be gathering, after years of false starts.

“This time is different, I believe,” says Vincent Mortier, group chief investment officer at Amundi, Europe’s largest asset manager with €2.2tn in assets under management. “The rebranding into ‘savings and investments union’ is not cosmetic, it is a meaningful change.”

Mortier says that CMU is needed “more than ever” to create an alternative to the US and to redirect savings towards productive investments in Europe. “What we hear from the European Commission and the European Central Bank is pretty reassuring. They get the urgency. But it is still a long way to converge with all stakeholders.”

For entrepreneurs such as Villig, the scale of the problems means Brussels has to move faster. “Unless this turns around, Europe doesn’t have an economic future,” he says. “Let’s be honest — if our best companies keep getting crushed or forced to move abroad, what’s left?”

The fragmentation of Europe’s system ranges from tax and regulations to insolvency.

Creditors of a small company that goes bust in Greece can on average expect to recover about 5 cents of every euro they are owed. In Luxembourg, they might recoup three-quarters of the debt, according to a 2023 European parliament briefing.

The gap is partly due to differences between countries in insolvency law, which sets out what happens to companies that can no longer meet their financial obligations.

“Insolvency rules are just like family law, [they’re] extremely entrenched in the fabric of each society,” says Boujnah. “Nevertheless, a proper insolvency law harmonisation could be a game-changer in the debt markets.”


The commission is considering targeted measures in non-bank insolvency law to provide greater legal certainty for investors. Although full convergence remains politically sensitive, officials suggest that a minimum standard approach could be feasible in key areas.

Insolvency is just one example of the lack of harmonisation across national frameworks within the EU. Others include inconsistent securities laws and differing tax treatments, both of which continue to deter cross-border investment and limit the scalability of EU capital markets.

Another structural obstacle is the sluggish pace of securitisation, or the practice of packaging financial assets, especially loans, into marketable securities. Once a vital tool for both companies and for investors, Europe’s securitisation market has struggled to recover since the financial crisis, held back in part by what market participants describe as overly complex and cautious regulation.

EU annual issuance of securitisation products stood at 0.3 per cent of GDP in 2022 — compared with 4 per cent in the US, where government-backed agencies such as Fannie Mae and Freddie Mac package up billions of dollars of home loans made by commercial banks into investment products.

Draghi called on Brussels to “adjust prudential requirements for securitised assets. Capital charges must be reduced for certain simple, transparent and standardised categories for which charges do not reflect actual risks.”

The commission has signalled a willingness to revisit the existing framework, aiming to allow more risk into the system, without compromising financial stability. 

“Maybe the level of risk we have now in the economy is not the right one,” EU financial services commissioner Maria Luís Albuquerque acknowledges in an interview with the Financial Times, adding that “it is challenging to get to the right calibration”.

The question of enforcement also looms large. Market participants and EU officials alike increasingly view stronger central supervision as critical to reducing fragmentation. A growing number of voices, chief among them France, are calling for an overhaul of the European Securities and Markets Authority (Esma), proposing that it be granted direct supervisory powers over large cross-border entities and key trading platforms — much like the US Securities and Exchange Commission. At present, all enforcement is carried out by national regulators.

The commission has pledged to move to a single supervisor for certain entities such as large clearing houses, cryptocurrency exchanges and big cross-border asset managers.

Industry groups have welcomed the move, but given the tortured history of capital market reform many remain cautious about the potential for meaningful change.

Calls for more market integration often clash with national interests, particularly in states such as Ireland and Luxembourg, which have large asset management sectors. That has resulted in resistance to moving supervision to the EU level.

“That’s the part of the debate that I really think must shift,” says Albuquerque. “It’s about guaranteeing the right outcome for Europe.”

Europe’s leading banks believe that the capital markets project — and a parallel initiative to create an EU-wide banking system — is vital for their competitiveness.

“The European banks and capital markets need one framework and one set of rules across our markets to support our bloc’s competitiveness, encourage investment, and empower the EU to be more than the sum of our parts,” says Andrea Orcel, chief executive of Italy’s UniCredit.

If there is one country in Europe that offers inspiration for bureaucrats hoping to turn savings into investment, it is Sweden.

Generations have grown up in the Nordic country with exposure to equities via pensions and public messaging. Broad tax-advantaged accounts like the investeringssparkonto (ISK) have normalised investment in stocks and funds across all social strata, creating a culture of participation that has deepened liquidity and allowed even small firms to raise money locally.

“We say it’s saving, but really, it’s investing,” says Swedish finance minister Elisabeth Svantesson. “It’s deeply cultural. Everyone, from left to right, understands this. And it channels money into innovation and companies,” she adds. “That’s why our capital markets work.”

Adam Kostyál, president of Nasdaq Stockholm, agrees. “We have to start with households . . . If you don’t have a strong bottom layer of investors, you can’t build a healthy public market.”


Sweden also has large investment groups, such as Wallenberg and Kinnevik, that can supply the so-called patient capital needed to turn start-ups into bigger companies. The country has produced two of Europe’s highest-profile tech companies, in the shape of streaming platform Spotify and payments group Klarna.

Sweden’s success highlights not only what could be possible across the continent, but also how far many countries still have to go. Most Europeans are wary of stock markets, unsure how to invest or fearful of losing their savings.

The result is that while Europeans save 15 per cent of household income, more than three times what Americans manage, that is mostly held in low-risk products such as savings accounts. Between 2015 and 2021, EU households held 32 per cent of their financial assets in cash and deposits, compared with just 13 per cent for US households, who put almost half their financial wealth into equities and investment funds​.

“It’s just sitting in completely the wrong asset classes, and it’s killing us,” says Villig.

The continent’s relatively generous publicly funded retirement and higher education systems also act as a disincentive. “If you want to retire in the US, you need to buy shares when you’re young,” Boujnah says. “In Europe, you hope someone else is still paying taxes when you’re old.”

Sceptics also point out that the project of creating an integrated capital market was difficult to achieve when the UK was in the EU, it could be even harder without the deep access to capital that the City of London enjoys.

EU officials acknowledge that completing the CMU will require sustained effort, member state co-operation and, at times, compromise.

The commission is exploring proposals that include enhancing financial literacy, introducing EU-wide investor labels and simplifying access to capital market products for retail investors. Officials argue that deeper retail participation is essential for market resilience and long-term financing of Europe’s green and digital transitions.

Some capitals, frustrated with drawn-out and often ineffective EU-wide efforts at integration, have suggested going deeper with fewer countries on certain aspects, such as the proposal for pan-European savings products, hoping that this will lead to a snowball effect.

“What we are going to see in the years to come is an acceleration of coalitions of the willing,” says Boujnah. Euronext is about to launch a pan-European equity prospectus in English, modelled on the S-1 registration form used by the SEC in the US. It is a move intended to lower the administrative burden and make IPOs more accessible across borders​.

Christian Noyer, a former governor of the French central bank and author of a report on capital markets for the commission, argues that efforts like these are crucial, but insufficient. “If we can’t create a true single market for capital, we’ll continue to lose our best companies to places where raising funds is simply easier,” he tells the Financial Times.

Villig warns that the consequences of past inaction are already visible. “Look at AI — why isn’t Mistral a €100bn company today?” he asks, referencing Europe’s best-known AI company. “If you don’t have the right capital, you can’t compete. And it’s not just about money — it’s about the ecosystem, the talent, the valuations. These things compound.”

He adds that even when European start-ups do manage to go public, many opt to list abroad, as Spotify did in 2018 and Klarna is planning to. “No founder wants to go to the US. We’re not running away — we’re being pushed,” he says. “[CEOs] think they’d get better valuations, more liquidity, more support in the US. That’s a huge red flag.”

What both supporters and critics of the EU’s push agree on is that reversing the drift in Europe’s capital markets will require a multipronged response to long-standing structural weaknesses. Financial literacy remains uneven, limiting public participation in markets. Retail investors continue to face barriers to entry, while pension systems in many member states offer limited incentives for equity investment.

Regulatory regimes, shaped by a post-crisis focus on risk reduction, may need to be rejigged to support growth. Finally, politics remain the main obstacle to meaningful progress on harmonising the EU’s fragmented rule book.

“This isn’t just about start-ups,” Villig concludes. “It’s about Europe’s place in the world. If we can’t figure out how to invest in our own future, someone else will — and then they will own it, instead of us.”

FT : Donald Trump seeks bromance and billions as he heads to Gulf

Donald Trump seeks bromance and billions as he heads to Gulf
US president expects flurry of deals on first official foreign trip but Israel’s war in Gaza is roiling the region

Donald Trump will touch down in Saudi Arabia this week for the first official foreign tour since he returned to the White House, with high expectations of securing a raft of multibillion-dollar deals. The biggest one of all, however, is likely to elude him.

The US president has made no secret of the fact that the lure of petrodollars from oil-rich Gulf states is the prime motivation for his visit, which will include stops in Qatar and the United Arab Emirates. Many of the US’s most powerful executives, including Elon Musk, Sam Altman and Larry Fink, are also expected to head to Riyadh.

But Trump is unlikely to achieve the goal he yearns for: a grand bargain that would lead to Saudi Arabia normalising relations with Israel, as its escalating 19-month war against Hamas in Gaza roils the region.

“Saudi Arabia wants to keep the focus on the visit on bilateral relations,” said Ali Shihabi, a Saudi commentator close to the royal court. “Normalisation is on the shelf unless Israel makes serious moves that Saudi Arabia wants, an end to the war and the establishment of a Palestinian state. Otherwise it’s going nowhere.”

This dissonance underlines that amid the glitz and dealmaking, Trump will discover how the dynamics in the Middle East have shifted since his last trip to Saudi Arabia in 2017.

The deals — real and aspirational — will still flow from the Gulf states, which traditionally favour Republican presidents, manage some of the world’s largest sovereign wealth funds and will fete Trump at lavish ceremonies.

While wary of the president’s unpredictability and the repercussions of his trade wars, the autocratic states embrace his transactional style, and welcome his dismissive attitude towards human rights.

“He’ll be flattered from one end of the Gulf to the other,” said Aaron David Miller, a former US diplomat. “And unlike Trump 1.0, there’s much more substance in play.”

Saudi Crown Prince Mohammed bin Salman has already pledged that Riyadh will invest $600bn in the US over four years; the UAE followed with a promise of $1.4tn over 10 years; and Qatar is expected to make its own investment pledge worth hundreds of billions of dollars during the Doha leg of Trump’s trip.

Analysts question how the Gulf states could deploy such a vast scale of capital in the timeframes, including Saudi Arabia as it grapples with lower oil prices and focuses on domestic projects.

The US is also in discussions with Qatar about Trump accepting a $400mn jumbo jet from Doha as a replacement for Air Force One, a move that has drawn criticism from the president’s supporters and opponents.

The US Treasury said on Thursday it would establish a “fast track process to facilitate greater investment in US businesses” from allies, something Gulf states lobbied for to accelerate artificial intelligence investments in the US and ease access to American chips.

Last month, Trump issued an executive order to relax restrictions on some weapons sales and to hasten procurement procedures, something Gulf states — among the biggest buyers of US weapons — have also sought.

As Trump champions his “America first” investment policy, the visiting American chief executives are set to attend a US-Saudi investment forum on Tuesday that will have a heavy focus on technology, AI and energy, and close with a flurry of investment announcements.

“This is not a geopolitical trip — a trip based on a strategic vision of the region,” said Dennis Ross, another former US diplomat. “In the first term there was a preoccupation with making announcements about big deals and investments combined with big US weapons sales. I expect we’ll see a replay of that.”

Yet Trump will not be able to ignore the clouds. Israel’s offensive in Gaza, launched in retaliation to Hamas’s October 7 2023 attack, has outraged Arab leaders, who fear generations of their young people will be radicalised by the carnage.

Prince Mohammed, who was edging close to a three-way deal with the US to normalise ties with Israel before the war erupted, has described Israel’s conduct in Gaza as “genocide” and insists Riyadh will not have diplomatic ties with Israel until a Palestinian state is established.

This has thwarted Trump’s hopes of expanding the so-called Abraham Accords he brokered in his first term that led to the UAE and three other Arab states formalising relations with Israel in 2020. But Saudi Arabia, a leader of the Sunni Muslim world, was always considered the grand prize and the key to getting other Arab and Muslim states to follow suit.

Trump will also find Gulf leaders pushing the US to reach a deal with Iran over the Islamic republic’s expansive nuclear programme as they fret about the risk of a new war erupting in the Middle East.

During Trump’s 2017 trip, a brash, younger Prince Mohammed and the UAE’s leader Sheikh Mohammed bin Zayed al-Nahyan were among Trump’s biggest cheerleaders as he prepared to pull the US out of the nuclear accord Tehran signed with the Barack Obama administration and other world powers.

This time around he will find Saudi Arabia and the UAE pursuing détente with Iran. Part of the reason is their experience during Trump’s first term, when his administration delivered what they deemed to be a tepid response after Iran was blamed for a missile and drone attack on Saudi Arabia’s oil infrastructure in 2019.

In Riyadh and Abu Dhabi, it was viewed as further evidence of the US’s unpredictability and questionable commitment to their security. Now they support a new deal with Iran to end the nuclear crisis, after the president initiated talks with Tehran but — along with Israel — also threatened military action if diplomacy fails.

“The Saudis and the UAE have realised that if Iran is really menaced and attacked, they will be the victims of a counterattack,” said Bernard Haykel, a professor of near eastern studies at Princeton University. “So I think the Saudis have been playing a very important mediating role and also a kind of tempering role with the Trump people.”

Saudi Arabia has also facilitated talks between the US and Russia, while Qatar is mediating between Israel and Hamas, alongside the US and Egypt.

Diplomats say Gaza and other regional crises will be on the agenda. But Michael Wahid Hanna of the Crisis Group questioned how much Gulf leaders are going to be willing to expend political capital on these issues amid the exuberant dealmaking.

“They can’t ignore it. But how central is it going to be?” he said. “The lead issue is going to be economics and they’re not going to want acrimony to undermine it.”

Washington has been pushing for a short-term truce to the war in Gaza to secure the release of a small number of the remaining 59 hostages held by Hamas, including Edan Alexander, the last American citizen still believed to be alive.

On Sunday, Hamas said it would release Alexander after it engaged directly with the US, in what appeared to be a goodwill gesture to Trump ahead of his trip. Mediators continue to work on efforts to secure a new ceasefire deal.

This comes as Israel threatens to expand its offensive, and move towards full occupation of the strip, which it says it will begin after Trump’s trip if there is no new ceasefire deal.

“You can’t avoid talking about Gaza, but the focus will be on the economic deals,” said a diplomat.

FT Lex : Trump’s drug price treatment is harsh but justified

Trump’s drug price treatment is harsh but justified
The US is the biggest market for prescription drugs, accounting for roughly $600bn of annual sales out of a global $1tn or so

“You get what you pay for” has a nice ring to it. But it does not accurately describe the situation of those buying prescription pharmaceuticals in the US. President Trump, who has vowed to lower drugs prices by as much as 80 per cent, may finally have found a useful target for his sledgehammer. 

Drug prices have been a long-standing headache for successive US administrations. The complex system through which private insurers and state programmes buy pharmaceuticals means they pay a multiple of what comparable products cost in other countries.


In 2022, gross prices — before discounts and rebates — were 2.8 times as high as those in 33 OECD comparison countries according to a study by Rand Corporation. That falls to 1.7 times including estimated discounts and rebates. 

Prescriptions to address this differential have so far proved ineffective. Trump tried — and failed — to lower prices in his first term. Whether his latest executive order — which the White House said would “communicate price targets to pharmaceutical manufacturers” and cut out intermediaries — will deliver concrete results remains to be seen.

Pharma companies will squeal. And with good reason. The US is by far the biggest market for prescription drugs, accounting for roughly $600bn of annual sales out of a global $1tn or so. Huge US companies — think AbbVie, Eli Lilly and Pfizer — derive between 70 and 90 per cent of their sales from it, according to Berenberg analysis. Europeans such as AstraZeneca, GSK and Sanofi are less exposed, but with 40-50 per cent of sales into the US they are hardly immune to this malady.


Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.

Yet it is hard to see a strong public policy justification for such costly US drugs. It is true that developing new therapies is a hit and miss endeavour, which requires the prospects of juicy returns for the winners. Less clear is why the US should shoulder such a disproportionate share of this burden. Indeed, a less lucrative US market might strengthen the hand of drugs companies in their negotiations with European national health services, meaning costs are more evenly shared out.

The US does derive some benefit from its position as the leading market for drugs. Biotech companies are mostly US based, and global drugmakers tend to seek a US license for their compounds before that of any other country. Conversely, with a penny-pinching National Health Service, England ranks sixth in the European rankings for new medicine availability, behind Germany, Italy, Austria, Switzerland and Spain. Yet the US has a thriving ecosystem, and a big market. There is probably quite a lot that it could do to cut the profit pool before innovation takes a nosedive.

If Trump did find a way of lowering US prices, it would be bitter pill for global pharmaceutical companies to swallow. The side effects and — in medical terms — interactions are uncertain. But based on the patient’s current condition, this blunt approach looks merited.

>>> US After Hours Summary: COIN +8.8% to join S&P 500; LSEA +58.4% to be acquir

After Hours Summary: COIN +8.8% to join S&P 500; LSEA +58.4% to be acquired; ODD -7.2% on share sale

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: GCT +16%, AIRJ +10%, MVST +8.8%, RLGT +6.7%, ACHC +5.5%, ARWR +4.7%, RPD +1.6%, SPG +0.9%, VTLE +0.9%, MRVI +0.9%, SARO +0.7%, HPK +0.6%, ZI +0.4%

Companies trading higher in after hours in reaction to news: LSEA +58.4% (to be acquired, will go private), COIN +8.8% (to join S&P 500), SATL +4.8% (enters into multi-million-dollar agreement with an Asia Pacific customer), BEAM +3.5% (FDA grants Regenerative Medicine Advanced Therapy designation to BEAM-302), MATX +1.9% (Director bought 2649 shares), AB +1.6% (reports April AUM), FDX +1.1% (FDX inks deal with AMZN, according to Business Insider), CATX +0.8% (provides update), GRAL +0.7% (new partnership with athenahealth), RPRX +0.7% (shareholder approval of its external manager acquisition), AX +0.5% (authorizes new $100 mln share repurchase program), AMC +0.4% (announces "50% Off Wednesdays" pricing initiative), EAT +0.1% (names new COO), CPA +0.1% (reports April traffic), CNR +0.1% (CEO bought 7500 shares), RTX +0.1% (awarded a $2.13 bln modification to Missile Defense Agency contract)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: DDD -26.1%, EXOD -16.6%, RGTI -13.2%, INDI -12.1%, XENE -8%, GETY -7.1%, AQST -7%, POWI -4.7% (also authorizes new $50 mln share repurchase program), HTZ -3.6%, CNNE -2.9%, BCO -0.9%, MODG -0.8%, RPAY -0.5% (also increases share repurchase authorization to $75 mln, concludes strategic review), IAS -0.4%, DVA -0.2%, MLNK -0.1% (also names new CEO)

Companies trading lower in after hours in reaction to news: ODD -7.2% (announces sale of 5.5 mln shares by co-founder and CEO), SGI -6.4% (prices 15,376,743 share offering at $62/sh), EDIT -4.4% (appeals ct remands patent interference to patent trial and appeal board), FOX -3.1% (launches AI-driven converged media platform), AEE -1.7% (stock offering), TNGX -1.5% (files for $400 mln mixed securities shelf offering), MMM -1.3% (resolves PFAS-related claims), QGEN -0.3% (acquries Genoox AI-powered software for $70 mln), CTRI -0.3% (files for $500 mln mixed securities shelf offering)

>>> What to look at today - 12th of May 2025

  • US equity-index futures and the dollar rose after China and the US made "substantial progress" on their trade talks, sparking optimism that trade tensions will decrease.
  • Global stocks rallied, with the Hang Seng Index advancing for an eighth day, and contracts for the S&P 500 and Nasdaq 100 jumping 1.5% and 2%, respectively.
  • The dollar strengthened against havens like the Swiss franc and yen, while gold tumbled 1.4% on easing demand for havens, and global bonds retreated with Treasury yields rising across the curve.



Nikkei Hang Seng CSI Shanghai Shenzen

Eur$ CNH CNY JPY GBP CHF RUB TRY WTI$ Gold BTC ETH

S&P Nasdaq EuroStoxx FTSE Dax SMI


Macro :
- Nuclear Stocks Climb on Report Trump to Speed Up Reactor Builds
- JPMorgan’s Dimon Criticizes Trump’s Approach to Tariffs: Fox
- Trump Opens Door to Tariffs on Commercial Aircraft, Engines (3)

Keep an eye on :
- AIR FP : Trump Opens Door to Tariffs on Commercial Aircraft, Engines
- ALM SM : Almirall 1Q Normalized Net Income Beats Estimates (1)
- ARAMCO AB :Saudi Aramco cuts its dividend by $10bn
- BBVA SM : Spain Said to Back Sabadell Tie-Up as Alternative to BBVA Deal
- CABK SM : CaixaBank Is Said to Explore Deal for Lone Star’s Novo Banco
- CTPNV NA : CTP Says 31.6%/Shareholders Choose Div in Cash, 68.4% in Shares
- BN FP : Danone to Buy Majority Stake in Kate Farms; No Terms
- EVK GY : Evonik 1Q Adjusted Ebitda Beats Estimates
- FRAS LN : Boohoo in Talks on £175 Million Debt Package, Telegraph Says
- HTZ US : Hertz Shares Jump After Pushing Debt Maturity Dates
- EMG LN : Man Group Is Said in Talks to Acquire Credit Firm Bardin Hill
- Monzo Bank IPO : Monzo Hires Bankers for Possible Listing Next Year, Sky Says
- NXT LN : Next CEO Wolfson Sells £12.4 Million of Shares at Near-Record
- NOVOB DC : Zepbound Patients Fear Losing Coverage After CVS Deal for Wegovy
- SAB SM : Spain Said to Back Sabadell Tie-Up as Alternative to BBVA Deal
- SAF FP : Trump Opens Door to Tariffs on Commercial Aircraft, Engines (3)
- SAN SM : Santander Rejected Bid of About £11 Billion for UK Unit, FT Says
- SGSN SW : SGS Expands Digital Trust Services With New AI Accreditation
- UN0 GY : Uniper to Shut Gas Storage Site Amid Market Pressure: Energate
- VLA FP : Valneva Says US FDA Recommends Ixchiq Pause in Elderly Patients
- VOW GY : Volkswagen Files Recall of 89,417 Vehicles: NHTSA
- X US : Nippon’s Mori to Talk US Steel Merger with Trump Admin: Semafor